Zepbound Market Impact - Search News

Order byBest matchMost fresh

News

Lilly, Wegovy and Zepbound

Zepbound trims more belly fat than Wegovy, study shows

Although Novo was first to market with Wegovy and its sister drug Ozempic for ... The company is also studying Zepbound’s impact on illness and death in a trial that’s due to deliver results in 2027. Patients who are more obese may ultimately do ...

Continue reading

Los Angeles Daily News · 2d

· 3d · on MSN

Lilly’s Zepbound Trims More Belly Fat Than Novo’s Wegovy

Eli Lilly's Zepbound outperforms Novo Nordisk's Wegovy for weight loss in trial

3d

Why Patients Are Being Forced to Switch to a 2nd-Choice Obesity Drug

CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...

13d

CVS Health Excludes Zepbound: Why Eli Lilly's 11%+ Drop Looks Overdone

Eli Lilly and Company's stock dropped 11% after CVS's Zepbound exclusion, but analysts see a mispricing opportunity. Click ...

8d

Beyond Valuation Ratios: 3 Undervalued Stocks To Buy In May 2025

Looking for undervalued stocks? Check out three top undervalued stocks to buy now in May, 2025 to boost your portfolio.

Zacks Investment Research on MSN1d

Lilly Down 17% Since Q1 Results: Should You Buy the Dip in LLY Stock?

Eli Lilly and Company’s LLY shares have lost 17% so far in May. Lilly announced mixed earnings results on May 1. It missed ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results